Cargando…
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatments. These variations, together with the emergence o...
Autores principales: | Cheema, Parneet K., Banerji, Shantanu O., Blais, Normand, Chu, Quincy S.-C., Desmeules, Patrice, Juergens, Rosalyn A., Leighl, Natasha B., Sheffield, Brandon S., Wheatley-Price, Paul F., Melosky, Barbara L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628757/ https://www.ncbi.nlm.nih.gov/pubmed/34898564 http://dx.doi.org/10.3390/curroncol28060386 |
Ejemplares similares
-
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023) -
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
por: Melosky, Barbara L., et al.
Publicado: (2023) -
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †
por: Bebb, D. Gwyn, et al.
Publicado: (2021) -
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer
por: Ionescu, Diana N., et al.
Publicado: (2022) -
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)